The Motley Fool··Jonathan PoncianoCommodore Capital Cuts Nuvalent Position by $84M Despite Strong Stock Performance
Commodore Capital cuts $84M Nuvalent stake to 3.68% despite 29% stock gains. Biotech firm awaits September PDUFA decision for lead drug candidate.
RLAYNUVLFDA approvalclinical trials